Loading...

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

WSE:BML
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BML
WSE
PLN54M
Market Cap
  1. Home
  2. PL
  3. Pharmaceuticals & Biotech
Company description

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The last earnings update was 117 days ago. More info.


Add to Portfolio Compare Print
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has significant price volatility in the past 3 months.
BML Share Price and Events
7 Day Returns
-2.2%
WSE:BML
6.4%
PL Biotechs
0.7%
PL Market
1 Year Returns
-42%
WSE:BML
-21.9%
PL Biotechs
-5.7%
PL Market
BML Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (BML) -2.2% -7.4% -16.3% -42% 7.4% -73.6%
PL Biotechs 6.4% 6.4% -9.2% -21.9% -13.6% 10.6%
PL Market 0.7% -0.2% 6.3% -5.7% 19% -6.6%
1 Year Return vs Industry and Market
  • BML underperformed the Biotechs industry which returned -21.9% over the past year.
  • BML underperformed the Market in Poland which returned -5.7% over the past year.
Price Volatility
BML
Industry
5yr Volatility vs Market

Value

 Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek.

WSE:BML Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year PL Government Bond Rate 2.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WSE:BML
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PL Govt Bond Rate 2.9%
Equity Risk Premium S&P Global 7.2%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.76
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.763 (1 + (1- 19%) (23.95%))
0.91
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.91
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (0.91 * 7.15%)
9.36%

Discounted Cash Flow Calculation for WSE:BML using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

WSE:BML DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (PLN, Millions) 4.60 4.48 4.37 4.25 4.15
Source Est @ -2.56% Est @ -2.56% Est @ -2.56% Est @ -2.56% Est @ -2.56%
Present Value
Discounted (@ 9.36%)
4.21 3.75 3.34 2.97 2.65
Present value of next 5 years cash flows PLN16.92
WSE:BML DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= PLN4.15 × (1 + 2.85%) ÷ (9.36% – 2.85%)
PLN65.50
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= PLN65.50 ÷ (1 + 9.36%)5
PLN41.88
WSE:BML Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= PLN16.92 + PLN41.88
PLN58.79
Equity Value per Share
(PLN)
= Total value / Shares Outstanding
= PLN58.79 / 62.26
PLN0.94
WSE:BML Discount to Share Price
Calculation Result
Value per share (PLN) From above. PLN0.94
Current discount Discount to share price of PLN0.87
= -1 x (PLN0.87 - PLN0.94) / PLN0.94
7.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is available for.
Intrinsic value
8%
Share price is PLN0.87 vs Future cash flow value of PLN0.94431
Current Discount Checks
For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:BML PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in PLN PLN0.20
WSE:BML Share Price ** WSE (2019-02-22) in PLN PLN0.87
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 23.17x
Poland Market PE Ratio Median Figure of 464 Publicly-Listed Companies 10.71x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek.

WSE:BML PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:BML Share Price ÷ EPS (both in PLN)

= 0.87 ÷ 0.20

4.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is good value based on earnings compared to the Europe Biotechs industry average.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is good value based on earnings compared to the Poland market.
Price based on expected Growth
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's expected growth come at a high price?
Raw Data
WSE:BML PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 4.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.74x
Poland Market PEG Ratio Median Figure of 101 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's assets?
Raw Data
WSE:BML PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in PLN PLN0.98
WSE:BML Share Price * WSE (2019-02-22) in PLN PLN0.87
Poland Biotechs Industry PB Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 1.59x
Poland Market PB Ratio Median Figure of 689 Publicly-Listed Companies 1.01x
WSE:BML PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:BML Share Price ÷ Book Value per Share (both in PLN)

= 0.87 ÷ 0.98

0.89x

* Primary Listing of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is good value based on assets compared to the PL Biotechs industry average.
X
Value checks
We assess BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek expected to grow at an attractive rate?
  • Unable to compare BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings growth to the Poland market average as no estimate data is available.
  • Unable to compare BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:BML Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 12.4%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10%
Poland Market Revenue Growth Rate Market Cap Weighted Average 6.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:BML Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:BML Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-09-30 17 -5 12
2018-06-30 31 -2 11
2018-03-31 30 -2 1
2017-12-31 31 4 1
2017-09-30 31 31 -23
2017-06-30 18 30 -25
2017-03-31 37 10 -26
2016-12-31 36 16 -26
2016-09-30 46 -4 -48
2016-06-30 45 -15 -45
2016-03-31 47 5 -35
2015-12-31 43 -3 -37

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is high growth as no earnings estimate data is available.
  • Unable to determine if BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:BML Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:BML Past Financials Data
Date (Data in PLN Millions) EPS *
2018-09-30 0.20
2018-06-30 0.16
2018-03-31 0.02
2017-12-31 0.01
2017-09-30 -0.51
2017-06-30 -0.61
2017-03-31 -0.60
2016-12-31 -0.58
2016-09-30 -1.08
2016-06-30 -1.02
2016-03-31 -0.80
2015-12-31 -0.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is trading at BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:BML Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 16.83 12.33 8.31
2018-06-30 31.20 11.03 15.90
2018-03-31 29.64 1.13 17.26
2017-12-31 31.40 0.59 17.99
2017-09-30 31.49 -22.51 18.64
2017-06-30 17.51 -24.76 13.77
2017-03-31 37.03 -26.42 20.40
2016-12-31 36.34 -25.80 20.03
2016-09-30 45.96 -47.76 21.43
2016-06-30 45.27 -45.28 18.13
2016-03-31 46.72 -35.39 17.53
2015-12-31 42.59 -37.24 16.57
2015-09-30 37.73 -2.35 13.69
2015-06-30 35.94 -2.17 13.08
2015-03-31 31.04 -2.15 12.00
2014-12-31 33.58 0.12 12.12
2014-09-30 27.68 -2.84 10.86
2014-06-30 28.77 -0.04 11.91
2014-03-31 30.51 0.46 12.85
2013-12-31 32.98 0.98 13.71
2013-09-30 31.54 -2.32 15.91
2013-06-30 26.34 -4.67 15.75
2013-03-31 24.62 -5.10 15.54
2012-12-31 24.85 -5.31 16.40
2012-09-30 31.11 0.33 15.95
2012-06-30 36.68 0.15 16.48
2012-03-31 38.20 -0.09 16.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Company Filings, last reported 4 months ago.

WSE:BML Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 60.74 12.97 0.35
2018-06-30 61.65 13.83 2.55
2018-03-31 62.46 13.30 2.63
2017-12-31 57.81 13.89 2.32
2017-09-30 37.48 33.47 19.42
2017-06-30 37.71 36.53 19.38
2017-03-31 47.73 38.44 6.29
2016-12-31 43.17 40.46 0.67
2016-09-30 7.06 0.00 0.18
2016-06-30 10.25 0.45 0.43
2016-03-31 20.04 0.45 0.91
2015-12-31 24.60 45.08 5.74
2015-09-30 52.79 0.45 0.27
2015-06-30 54.64 0.43 0.09
2015-03-31 54.99 0.45 0.20
2014-12-31 57.25 29.27 0.38
2014-09-30 56.49 31.15 19.29
2014-06-30 58.49 29.40 9.58
2014-03-31 58.50 29.46 1.45
2013-12-31 57.13 25.14 0.47
2013-09-30 46.58 19.95 0.11
2013-06-30 45.45 19.65 0.29
2013-03-31 45.29 19.04 0.26
2012-12-31 44.75 29.09 2.08
2012-09-30 48.90 6.33 0.13
2012-06-30 50.11 21.56 18.19
2012-03-31 50.39 21.62 0.69
  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's level of debt (21.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (42.9% vs 21.4% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 7.2x coverage).
X
Financial health checks
We assess BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek dividends.
If you bought PLN2,000 of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:BML Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Poland Market Average Dividend Yield Market Cap Weighted Average of 209 Stocks 3.3%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.4%
Poland Bottom 25% Dividend Yield 25th Percentile 2.6%
Poland Top 25% Dividend Yield 75th Percentile 7.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has not reported any payouts.
  • Unable to verify if BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marcin Piróg
COMPENSATION PLN185,000
CEO Bio

Mr. Marcin Piotr Piróg serves as Chief Executive Officer of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna. Mr. Piróg served as the President of LOT Polish Airlines S.A. from November 2010 to December 2012 and also served as its Member of Management Board until December 2012. He served as the Chief Executive Officer of RUCH S.A. He served as Chief Executive Officer of LOT Polish Airlines from November 2010 to December 2012. He served as Chief Executive Officer of Carlsberg Polska, Poland of Carlsberg A/s. He was Chairman and Co-owner of InDreams from November 2008 to October 2010. Mr. Piróg served as President of the Management Board of Carlsberg Polska SA (Formerly Known as Carlsberg Okocim SA.) from May 16, 2000 to July 2008 and its Member of the Management Board since May 16, 2000. He is a graduate from Harvard University in 2003. He holds MBA in Management from INSEAD from 1992 to 1993 and MSc in Engineering from Institut national polytechnique de Lorraine from 1982 to 1985.

CEO Compensation
  • Insufficient data for Marcin to compare compensation growth.
  • Marcin's remuneration is higher than average for companies of similar size in Poland.
Management Team

Marcin Piróg

TITLE
Chief Executive Officer
COMPENSATION
PLN185K

Wlodzimierz Parzydlo

TITLE
CFO & Member of Management Board
COMPENSATION
PLN70K

Piotr Fic

TITLE
Member of the Management Board for Operational Matters
AGE
50

Katarzyna Krukowoska

TITLE
Head Accountant
Board of Directors

Jaroslaw Blaszczak

TITLE
Chairman of the Supervisory Board
COMPENSATION
PLN68K

Wiktor Napióra

TITLE
Vice Chairman of the Supervisory Board
COMPENSATION
PLN93K

Waldemar Sierocki

TITLE
Member of Supervisory Board
COMPENSATION
PLN1,000

Dariusz Kucowicz

TITLE
Member of Supervisory Board
COMPENSATION
PLN232K
TENURE
11.1 yrs

Piotr Kwasniewski

TITLE
Member of the Supervisory Board
COMPENSATION
PLN1,000

Tomasz Jasny

TITLE
Member of the Supervisory Board

Konrad Miterski

TITLE
Member of the Supervisory Board
COMPENSATION
PLN1,000

Andrzej Szostek

TITLE
Supervisory Board Member
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Investor Composition Influence The Stock Price?

The big shareholder groups in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. … BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is not a large company by global standards. … Check out our latest analysis for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

Simply Wall St -

Should We Be Delighted With BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA's (WSE:BML) ROE Of 20%?

We'll use ROE to examine BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA (WSE:BML), by way of a worked example. … Over the last twelve months BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has recorded a ROE of 20%. … View our latest analysis for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek?

Simply Wall St -

What Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA's (WSE:BML) Ownership Structure Look Like?

Today, I will be analyzing BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA’s (WSE:BML) recent ownership structure, an important but not-so-popular subject among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … See our latest analysis for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

Simply Wall St -

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA (WSE:BML): Can It Deliver A Superior ROE To The Industry?

This analysis is intended to introduce important early concepts to people who are starting to invest. … and want to begin learning the link between BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA (WSE:BML)’s return fundamentals and stock market performance. … BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA’s (WSE:BML) most recent return on equity was a substandard 1.80% relative to its industry performance of 17.03% over the past year.

Simply Wall St -

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA. (WSE:BML): How Does It Impact Your Portfolio?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … BML’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … As a result, this aspect of BML indicates a higher beta than a similar size company with a lower portion of fixed assets on their balance sheet.

Simply Wall St -

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA.'s (WSE:BML) Latest Financial Perfomance Look Strong?

In this commentary, I will examine BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek SA.'s (WSE:BML) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, as well as how the rest of the biotechs industry performed. … Check out our latest analysis for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Did BML's recent earnings growth beat the long-term trend and the industry? … WSE:BML Income Statement Mar 30th 18 We can further evaluate BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Company Info

Map
Description

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 and Gamma anty-HBs 1000 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker’s fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland.

Details
Name: BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
BML
Exchange: WSE
Founded: 1944
PLN54,166,556
62,260,410
Website: http://biomedlublin.com
Address: BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
ul. Uniwersytecka 10,
Lublin,
20-029,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE BML Common Bearer Shares Warsaw Stock Exchange PL PLN 29. Jul 2011
LSE 0RKM Common Bearer Shares London Stock Exchange GB PLN 29. Jul 2011
Number of employees
Current staff
Staff numbers
0
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/23 22:04
End of day share price update: 2019/02/22 00:00
Last earnings filing: 2018/10/29
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.